KURA ONE, Compact Cans of Japanese Sake Featuring Brands From Award-winning Sake Breweries in Japan and Overseas, Is Now Available as a Subscription Service Delivered Worldwide!
28.2.2023 11:00:00 EET | Business Wire | Press release
KURA ONE meticulously selects sake from brands of award-winning sake breweries in Japan and overseas and repackages them in compact and easy-to-handle 180ml/196g aluminum cans, while maintaining the quality of the sake. On January 31, the first canned sake subscription service in the world that delivers sake, along with stories about enjoying sake, directly to customers via subscription in more than 100 countries has launched online ordering. As a result of the service's introduction in numerous media sources, it has been attracting attention in Japan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230223006067/en/
Sake breweries from different regions also participated in the press conference. (Photo: Business Wire)
“KURA ONE Sales Commemorative Special Edition,” which is a complete set of all 21 brands to be delivered from January to June 2023, and the Assortment Box with special sake containers featuring Japanese craftsmanship are very popular.
Also, KURA ONE's brand movie "KURA ONE TRIP." which introduces sake breweries and their regions is now online. On February 28 (Tue.), KURA ONE begins accepting applications worldwide for BtoB partners (restaurants, sake retailers, etc.) who can place orders for as little as 30 cans.
Video of press conference in Tokyo (English version): https://www.youtube.com/watch?v=aTTeue_Y2Ig
KURA ONE TRIP.: https://sake.japanpage.jp/en/pages/kuraone_movies
[Six new Collections. Now shipping to 100 countries around the world!]
-
“KURA ONE STORY. Subscription”: 3-4 cans of brands from domestic and international award-winning sake breweries delivered each month.
Price: 3,600 yen (tax not included) per month, limited to the first 2,000 slots - “KURA ONE Sales Commemorative Special Edition”: a special complete set of 21 cans of brands from award-winning sake breweries in Japan and overseas. Price: 23,000 yen (without tax) and limited to the first 500 sets.
- "KURA ONE Glass Sake Cup Box": includes 4 types of sake glasses of Kimoto Glassware used in famous restaurants, and 2 cans of KURA ONE. Price: 16,800 yen (without tax) and limited to the first 100 sets.
- "KURA ONE Traditional Craft Sake Cup Box": includes 3 types of traditional craft sake vessels such as Ceramic (Shigaraki) and Porcelain (Kutani) and 2 cans of KURA ONE. Price: 7,600 yen (without tax) and limited to the first 100 sets.
- "KURA ONE Temperature Sensitive Sake Cups Box": includes 2 mysterious sake vessels whose cherry blossom color changes depending on the sake temperature, and 2 cans of KURA ONE. Price: 5,400 yen (without tax) and limited to the first 100 sets.
- "KURA ONE Gacha Box": an experimental box for starters. You will enjoy 2 cans of KURA ONE after they arrive. Price: 1,700 yen (without tax)
- Shipping fees and taxes not included.
Click here to purchase (on the official website):
English: https://sake.japanpage.jp/en/pages/kuraone
French: https://sake.japanpage.jp/fr/pages/kuraone
Traditional Chinese: https://sake.japanpage.jp/zh-tw/pages/kuraone
Simplified Chinese: https://sake.japanpage.jp/zh-cn/pages/kuraone
Japanese: https://sake.japanpage.jp/pages/kuraone
[Now accepting applications for BtoB partners worldwide]
We are seeking BtoB sales partners to create new sake drinking scenes that integrate with the lifestyles of consumers in various parts of the world.
KURA ONE places importance on its target users and sales method. We will interview each company to make decisions based on the proposal content and their enthusiasm for the project, rather than on a first-come, first-served basis. This is not an exclusive offer for one company in one country. Currently, we have begun to conclude business negotiations with restaurants and sake retailers in Asia, Europe, and the United States.
Overview of BtoB sales partnerships / Transaction details / Privileges / How to apply (5 languages): https://sake.japanpage.jp/en/pages/kuraone_btob
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230223006067/en/
Contact information
KURA ONE
Public Relations: Tomoko Takiguchi
+81-80-8422-5844
info@greencreate.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom